参考文献/References:
[1] 马丽媛,吴亚哲,陈伟伟. 《中国心血管病报告2018》要点介绍.中华高血压杂志[J].2019,27(8):712-716.
[2] 国家卫生计生委合理用药专家委员会,中国医师协会高血压专业委员会. 高血压合理用药指南(第2版)[J]. 中国医学前沿杂志（电子版）,2017,7:28-126.
[3] Schmieder RE,Redon J,Grassi G,et al. ESH position paper:renal denervation - an interventional therapy of resistant hypertension[J]. J H ypertens,2012,30(5):837-841.
[4] Yugar-Toledo JC,Modolo R,de Faria AP,et al. Managing resistant hypertension:focus on mineralocorticoid-receptor antagonists[J].Vasc Health Risk Manag,2017,13:403-411.
[5] Aronow WS. Approaches for the management of resistant hypertension in 2020[J]. Curr Hypertens Rep,2020,22(1):3.
[6] 王引利. 难治性高血压及其非介入治疗进展[J]. 心血管病学进展,2018,39(5):823-827.
[7] Hwang AY,Dave C,Smith SM. Trends in antihypertensive medication use among us patients with resistant hypertension,2008 to 2014[J]. Hypertension,2016,68(6):1349-1354.
[8] Siddiqui M,Calhoun DA. Refractory versus resistant hypertension[J]. Curr Opin Nephrol Hypertens,2017,26(1):14-19.
[9] Bader M. Tissue renin-angiotensin-aldosterone systems:targets for pharmacological therapy[J]. Annu Rev Pharmacol Toxicol,2010,50:439-465.
[10] Le Jemtel TH,Richardson W,Samson R,et al. Pathophysiology and potential non-pharmacologic treatments of obesity or kidney disease associated refractory hypertension[J]. Curr Hypertens Rep,2017,19(2):18.
[11] Koenig JB,Jaffe IZ. Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling:novel mechanisms and clinical implications[J]. Curr Hypertens Rep2014,16(5):427.
[12] Shashar M,Hod T,Chernichovski T,et al. Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells[J]. Nitric Oxide,2018,80:24-31.
[13] Lu Q,Davel AP,Mcgraw AP,et al. PKCδ mediates mineralocorticoid receptor activation by angiotensin ⅱ to modulate smooth muscle cell function [J]. Endocrinology,2019,160(9):2101-2114.
[14] Salles GF,Ribeiro FM,Guimaraes GM,et al. A reduced heart rate variability is independently associated with a blunted nocturnal blood pressure fall in patients with resistant hypertension[J]. J Hypertens,2014,32(3):644-651.
[15] Grassi G,Mark A,Esler M. The sympathetic nervous system alterations in human hypertension[J]. Circ Res,2015,116(6):976-990.
[16] Raheja P,Price A,Wang Z,et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients[J]. Hypertension,2012,60(2):319-325.
[17] Genovesi S,Brambilla P,Giussani M,et al. Insulin resistance,prehypertension,hypertension and blood pressure values in paediatric age[J]. J Hypertens,2012,30(2):327-335.
[18] Ogino K,Kinugasa Y,Kato M,et al. Spironolactone,not furosemide,improved insulin resistance in patients with chronic heart failure[J]. Int J Cardiol,2014,171(3):398-403.
[19] Good ME,Chiu YH,Poon IKH,et al. Pannexin 1 channels as an unexpected new target of the anti-hypertensive drug spironolactone[J]. Circ Res,2018,122(4):606-615.
[20] Arhancet GB,Woodard SS,Dietz JD,et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines[J]. J Med Chem,2010,53(10):4300-4304.
[21] Vaclavik J,Sedlak R,Plachy M,et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT):a randomized,double-blind,placebo-controlled trial[J]. Hypertension,2011,57(6):1069-1075.
[22] Zhao D,Liu H,Dong P,et al. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension[J]. Int J Cardiol,2017,233:113-117.
[23] Williams B,Macdonald TM,Morant S,et al. Spironolactone versus placebo,bisoprolol,and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):a randomised,double-blind,crossover trial[J]. Lancet,2015,386(10008):2059-2068.
[24] Krieger EM,Drager LF,Giorgi DMA,et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension:the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment)[J]. Hypertension,2018,71(4):681-690.
[25] Rosa J,Widimsky P,Waldauf P,et al. Role of adding spironolactone and renal denervation in true resistant hypertension:one-year outcomes of randomized PRAGUE-15 study[J]. Hypertension,2016,67(2):397-403.
[26] Oliveras A,Armario P,Sans L,et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone:The DENERVHTA (Denervacion en Hipertension Arterial) study[J]. J Clin Hypertens(Greenwich),2018,20(1):69-75.
[27] Tam TS,Wu MH,Masson SC,et al. Eplerenone for hypertension[J].Cochrane Database Syst Rev,2017,2(2):CD008996.
[28] Karns AD,Bral JM,Hartman D,et al. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension[J]. J Clin Hypertens,2013,15(3):186-192.
[29] Krasinska B,Cofta S,Szczepaniak-Chichel L,et al. The effects of eplerenone on the circadian blood pressure pattern and left ventricular hypertrophy in patients with obstructive sleep apnea and resistant hypertension-a randomized,controlled trial[J]. J Clin Med,2019,8(10):1671.
[30] Schneider A,Schwab J,Karg MV,et al. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension[J]. J H ypertens,2017,35(5):1086-1092.
[31] Bramlage P,Swift SL,Thoenes M,et al. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease[J]. Eur J H eart Fail,2016,18(1):28-37.
[32] Kolkhof P,Delbeck M,Kretschmer A,et al. Finerenone,a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury[J]. J Cardiovasc Pharmacol,2014,64(1):69-78.
[33] Ruilope LM,Nowack C,Bakris GL. Masked and nocturnal hypertension in the ARTS-DN ABPM Sub-Study with finerenone[J]. J Am Soc Hypertens,2016,10(suppl 1):1-9.
[34] Ito S,Itoh H,Rakugi H,et al. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)[J]. Hypertension,2020,75(1):51-58.
[35] Derosa G,Gaudio G,Pasini G,et al. A randomized,double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients[J]. Drug Des D evel Ther,2018,12:2611-2666.
[36] Kolkhof P,Borden SA. Molecular pharmacology of the mineralocorticoid receptor:prospects for novel therapeutics[J]. Mol Cell Endocrinol,2012,350(2):310-317.
[37] Vaclavik J,Sedlak R,Jarkovsky J,et al. Effect of spironolactone in resistant arterial hypertension:a randomized,double-blind,placebo-controlled trial (ASPIRANT-EXT)[J]. Medicine,2014,93(27):162-171.
[38] Korol S,Mottet F,Perreault S,et al. A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis[J]. Medicine,2017,96(48):8719-8142.
[39] Lentini S,Heinig R,Kimmeskamp-Kirschbaum N,et al. Pharmacokinetics,safety and tolerability of the novel,selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies[J]. Fundam Clin Pharmacol,2016,30(2):172-184.